pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. The exact mechanism depends on the disease in question.

Gene Editing 142

Gene Editing Gene Gene Therapy In-Vivo 142

Pharmaceutical Technology

JANUARY 24, 2023

The investigational adeno-associated virus (AAV) gene therapy candidate NGN-401 is claimed to be the first to deliver the full-length human MECP2 gene using the company’s Expression Attenuation via Construct Tuning (EXACT) gene regulation technology.

Gene Therapy 208

Gene Therapy Gene Gene Expression Regulation 208

Drug Discovery World

APRIL 17, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

APRIL 11, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

APRIL 3, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel.

Genome 52

Genome Genomics Gene Expression RNA 52

Drug Discovery World

MARCH 27, 2024

It will also feature an introduction by Melanie Masuda, Director of Market Development, ScaleBio. Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel.

Genome 52

Genome Genomics Gene Expression RNA 52

Pharmaceutical Technology

JUNE 13, 2023

The aberrant protein complex is essential for regulating leukaemia-promoting gene expression. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. It received fast track and breakthrough designation from the FDA and is poised to be first to market.

Gene Expression 130

Gene Expression Protein Sales Genetics 130

Delveinsight

JULY 24, 2021

The necessity of a robust Angelman syndrome pipeline is indispensable at the current moment because of a shortage of any approved therapy option available in the market. Companies like Roche , Biogen , Ovid therapeutics , and Ionis , are among several companies that are finding potential cure taking forward Angelman syndrome market.

Gene Therapy 96

Gene Therapy Gene Expression Gene RNA 96

Delveinsight

JANUARY 18, 2021

Angelman syndrome is a result of the missing or dysfunctional gene known as UBE3A. The gene is responsible for the normal and healthy development of an individual physically as well intellectually. The present Angelman syndrome treatment market revolves around the management of symptoms rather than curing the condition. .

Marketing 52

Marketing Gene Drugs Protein 52

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. greater safety, transient and reversible effect on gene expression).

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

Drug Discovery World

OCTOBER 17, 2022

By Dr Christof Gänzler, Product Marketing Biology at PerkinElmer Informatics. . In today’s quest to accelerate time to market for novel drugs, part of the success formula requires leveraging discovery data with more precision and speed, and earlier in the process. It takes more than speed to advance and maintain performance.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

Drug Discovery World

NOVEMBER 29, 2022

The AI designs synthetic DNA, where it is easy to modify its regulatory information in the desired direction of gene expression. . With our technology, it is possible to develop and manufacture proteins much more efficiently so that they can be marketed,” added Zelezniak. . . The next step is to use human cells.

DNA 52

DNA Development Research Drugs 52

Drug Discovery World

JULY 10, 2023

Artificial intelligence (AI), gene editing, synthetic biology and more, are beginning to prove their usefulness in drug design and development, taking therapies away from the one-size-fits-all approach, towards more definable targets that operate more effectively. There are myriad ways that this is being enabled.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

pharmaphorum

JANUARY 13, 2022

Recall that KRAS was considered an undruggable target for decades before Amgen found a suitable binding region on the protein and bought an inhibitor to market for lung cancer. New R&D techniques that have unlocked the 3D structure of complex molecules have, however, started to render the term obsolete.

Protein 57

Protein Gene Expression Regulation Gene 57

Roots Analysis

AUGUST 31, 2023

According to a study, around 20,000 genes are present in the human body, all of which interact with the nutrients in the food, either directly or indirectly. For instance, carbohydrates increase the expression of genes responsible for the synthesis of enzymes and transporters involved in their metabolism.

Genome 40

Genome Genomics Genetics Gene 40

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. RNA interference (RNAi) Therapeutics : Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials 57

Trials Gene Silencing RNA Gene Expression 57

Roots Analysis

JANUARY 14, 2024

This can be attributed to the fact that the production of biopharmaceuticals requires living expression systems. Usually, the desired gene, such as human insulin gene, when inserted into the plasmid of the host cell uses transcriptional and translational machinery of the host to express itself.

Contract Manufacturing 40

Contract Manufacturing Manufacturing Protein Bacteria 40

Drug Discovery World

JANUARY 24, 2024

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. PW: Through our exclusive access to one of the world’s largest fibrosis tissue biobanks, we have correlated disease progression to gene expression data, enabling us to discover novel targets on the pathway that drives the advanced stages of fibrotic disease.

Research 59

Research Gene Expression Drugs Development 59

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

MARCH 7, 2024

Industry professionals will explore the market, innovative formulations and nutritional solutions tailored to empower women toward optimal health and well-being. A significant 58 percent of women worldwide have heightened their use of supplements to support overall wellness.

Hormones 115

Hormones Genetics Genome Genomics 115

Delveinsight

JULY 30, 2020

Omega’s platform is designed to adjust gene expression to healthy levels rather than switching genes on and off. The work of the company is based on the genes and their regulatory elements found in loops of DNA called Insulated Genomic Domains (IGDs). GSK culls a host of pipeline meds after failures, prioritization.

Genome 52

Genome Genomics Antibody Gene 52

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

Drug Discovery World

APRIL 30, 2024

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. However, these therapies can cause severe adverse effects.

RNA 52

RNA Protein Vaccination Vaccine 52

XTalks

MARCH 22, 2021

The mega biotech acquisition deals, ranging between a quarter to over half a billion dollars, reflects the expanding oncology market, which was valued at $136.7 Despite setbacks due to the pandemic, the market is expected to recover and continue its march forward. The liquid biopsy market itself was valued at over $1.06

Life Science 110

Life Science Development Marketing Gene Expression 110

Drug Discovery World

APRIL 21, 2023

Companies selected for Innovation AveNEW, and who opt-in to compete for the SLAS Ignite Award, will be judged by an SLAS panel on a combination of key concepts, including their marketing plan, market presence and potential, funding prospects, plan for growth and the existence of balanced company leadership, among other qualities.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. Developing new drugs is a costly and time-consuming process, and many promising drugs fail to make it to market due to financial constraints.

Development 40

Development Drugs Trials FDA Approval 40

The Pharma Data

DECEMBER 14, 2020

“We believe aligning with one of the largest and fastest growing companies in China’s NGS-based cancer therapy selection market speaks to the strength of DetermaRx as a valuable treatment stratification tool to help clarify this critical treatment decision point in early stage tumors. About Burning Rock.

Licensing 52

Licensing Licensing Marketing Gene Expression 52

Drug Discovery World

NOVEMBER 15, 2022

If you want to order gene-length sequences, rather than short oligos for PCR, the waiting times are around two or three weeks at least. Modern advances in DNA synthesis, however, have made it possible to leverage gene-to- antibody production platforms where input candidate DNA sequences can be turned into purified antibodies.

DNA 98

DNA Drugs Antibody Engineer 98

The Pharma Data

AUGUST 3, 2021

Istodax remains on the market for treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.

Nurses 52

Nurses In-Vitro Gene Expression Medicine 52

The Pharma Data

NOVEMBER 9, 2020

The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. EMJ Allergy Immunol.

Trials 52

Trials Production Sales Manufacturing 52